PDL BioPharma, Inc. (PDLI): Price and Financial Metrics
GET POWR RATINGS... FREE!
PDLI Stock Price Chart Interactive Chart >
PDLI Price/Volume Stats
|Current price||$2.47||52-week high||$3.86|
|Prev. close||$2.70||52-week low||$2.09|
|Day high||$2.78||Avg. volume||1,480,534|
|50-day MA||$2.42||Dividend yield||N/A|
|200-day MA||$2.92||Market Cap||282.14M|
PDL BioPharma, Inc. (PDLI) Company Bio
PDL BioPharma Inc. manages a portfolio of patents and royalty assets related to the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company was founded in 1986 and is based in Incline Village, Nevada.
Most Popular Stories View All
PDLI Latest News Stream
|Loading, please wait...|
PDLI Latest Social Stream
View Full PDLI Social Stream
Latest PDLI News From Around the Web
Below are the latest news stories about Pdl Biopharma Inc that investors may wish to consider to help them evaluate PDLI as an investment opportunity.
PDL BioPharma, Inc. (NASDAQ:PDLI) major shareholder Silver Point Capital L.P. bought 640,000 shares of the firm’s stock in a transaction that occurred on Monday, December 14th. The stock was purchased at an average cost of $2.62 per share, with a total value of $1,676,800.00. The acquisition was disclosed in a filing with the Securities & […]
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]
PDL BioPharma ([[PDLI]] +5.2%) has entered into a Capital Provision Agreement with Epps Investments LLC. Under the terms, Epps to pay PDL ~$51.39M no later than December 31, 2020, in exchange for 100% of the payments received by PDL on or after the date of the Agreement pursuant to the...
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020, in exchange for 100% of the payments or other property or value received by PDL on or after the date of the Agreement pursuant to the settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) ("Wellstat Diagnostics") announced August 12, 2020, and the underlying claims resolved by the Settlement Agreement. The Settlement Agreement resolved previously reported litigation relating to loans made to Wellstat Diagnostics by PDL. PDL has agreed to ...
INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq")….
PDLI Price Returns